ALNY 10-K Annual Reports

Alnylam Pharmaceuticals, Inc. (ALNY) has filed its 10-K for the fiscal year ending on December 31, 2025, highlighting a robust portfolio of six approved RNAi therapeutics and a promising clinical pipeline. The company is executing its "Alnylam 2030" strategy, aiming for significant revenue growth and expansion into new therapeutic areas and tissue types. Key advancements include the recent approvals and ongoing launches of AMVUTTRA for ATTR amyloidosis with cardiomyopathy, and Qfitlia for hemophilia. The company also reported positive clinical trial data for nucresiran, a next-generation ATTR therapy, and zilebesiran for hypertension, underscoring its commitment to innovation and continued pipeline progression. Financially, Alnylam has managed its capital structure by issuing convertible notes and repurchasing existing ones, while also establishing a significant revolving credit facility to support ongoing operations and growth. The company's focus on genetically validated targets and advanced delivery technologies, such as GalNAc conjugates and C16 moieties, positions it to address a wide range of diseases with high unmet needs. Investors should monitor the continued commercial success of its approved products, progress in late-stage clinical trials, and the strategic expansion into prevalent diseases.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed its 2024 10-K report, highlighting significant progress in its RNAi therapeutics pipeline and commercialization efforts. The company has five approved products: ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Leqvio (commercialized by Novartis). A key development is the filing of a supplemental New Drug Application (sNDA) for AMVUTTRA for ATTR amyloidosis with cardiomyopathy, with a target action date from the FDA set for March 23, 2025. The company also reported strong revenue from its TTR franchise, with ONPATTRO and AMVUTTRA generating $252.9 million and $970.5 million in global net product revenues, respectively, for 2024. Furthermore, GIVLAARI and OXLUMO contributed $255.9 million and $167.1 million in global net revenues. Alnylam continues to advance its "Alnylam P5x25" strategy, aiming to become a top-tier biotech company by the end of 2025. The company ended 2024 with a robust cash position of $2.69 billion, indicating financial stability and the ability to fund ongoing operations and development without immediate need for equity financing. The pipeline features several promising late-stage candidates, including zilebesiran for hypertension, nucresiran for ATTR amyloidosis, and mivelsiran for Alzheimer's disease, with significant updates expected in 2025 from clinical trials and regulatory submissions.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its 2023 financial and operational results, showcasing significant revenue growth driven by its expanding portfolio of RNAi therapeutics. The company's net product revenues reached $1.24 billion, up 39% year-over-year, primarily due to the strong performance of AMVUTTRA and continued growth in GIVLAARI and OXLUMO, partially offset by a decline in ONPATTRO sales as patients transitioned to AMVUTTRA. Collaboration revenues also saw a substantial increase, largely from the new agreement with Roche for zilebesiran and increased royalties from Novartis on Leqvio. Alnylam continues to invest heavily in research and development, with expenses increasing by 14% to $1.0 billion, reflecting progress in its pipeline, including the development of zilebesiran for hypertension and ALN-APP for Alzheimer's disease. The company ended the year with $2.44 billion in cash, cash equivalents, and marketable securities, providing a solid liquidity position. Despite a net loss of $440 million, Alnylam is progressing towards its P5x25 strategic goals, aiming for profitability and a leading biotech profile by the end of 2025.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its 2022 financial and operational results in its Form 10-K filed on February 23, 2023. The company demonstrated significant growth in net product revenues, primarily driven by its ATTR amyloidosis franchise, with ONPATTRO and AMVUTTRA generating substantial revenue. The company is strategically advancing its pipeline with a focus on both rare and prevalent diseases, highlighted by progress in late-stage investigational programs. Financially, Alnylam ended 2022 with a strong cash position of $2.19 billion, supporting its operations and future development. The company also successfully raised $1.04 billion through convertible senior notes, with proceeds primarily used to repay existing debt. Alnylam remains committed to its P5x25 strategy, aiming to become a top-tier biotech company by 2025 through sustainable innovation and strong financial performance. Despite a reported net loss for the year, the company shows a positive trajectory with growing product revenues and a robust pipeline, positioning it for potential long-term value creation.

Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2021 performance, highlighting continued growth in its approved RNAi therapeutics portfolio with ONPATTRO, GIVLAARI, and OXLUMO. The company is advancing its "Alnylam P5x25" strategy, aiming to become a top five biotech company by 2025, with ambitious goals for patient reach, product launches, pipeline expansion, revenue growth, and profitability. Key developments include the FDA approval of Leqvio (inclisiran) for heterozygous familial hypercholesterolemia (HeFH) and clinical data for vutrisiran in ATTR amyloidosis, positioning it for potential regulatory approval. Financially, Alnylam ended 2021 with substantial cash reserves, but also reported an operating loss, reflecting ongoing investment in its pipeline and commercialization efforts. The company's strategic financing collaboration with Blackstone provided significant capital. Alnylam continues to navigate a competitive landscape and manages various risks, including those related to regulatory approvals, clinical trial outcomes, intellectual property, and market access.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its financial and operational highlights for the fiscal year ending December 31, 2020. The company, a leader in RNAi therapeutics, continues to advance its commercial-stage pipeline with four approved products: ONPATTRO®, GIVLAARI®, OXLUMO™, and Leqvio® (partnered with Novartis). Despite a net loss of $858.3 million for the year, the company demonstrated significant revenue growth, with total revenues reaching $492.9 million, a 124% increase year-over-year, driven by strong performance of ONPATTRO and GIVLAARI and the initial launch of OXLUMO. Key strategic advancements include progress on the APOLLO-B and HELIOS-B Phase 3 studies for ATTR amyloidosis with cardiomyopathy, positive topline results from the HELIOS-A Phase 3 study for vutrisiran, and the ongoing development of multiple early-stage pipeline candidates. Alnylam also secured a significant financing collaboration with Blackstone, providing up to $2 billion to support its growth initiatives, including the ambitious "Alnylam P5x25" strategy aimed at becoming a top five biotech company by market capitalization by the end of 2025. The company ended the year with a strong cash position of $1.87 billion, providing a solid foundation for future investments in research, development, and commercialization.

Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2019 Annual Report (10-K) on February 13, 2020, highlighting significant progress in its RNA interference (RNAi) therapeutics platform. The company achieved key milestones, including the U.S. FDA approval and launch of GIVLAARI for acute hepatic porphyria (AHP) and continued commercialization of ONPATTRO for hereditary transthyretin-mediated amyloidosis (hATTR) polyneuropathy, which generated $166.4 million in net revenue in 2019. Alnylam's "Alnylam 2020" strategy is on track, with a robust pipeline focused on four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases, and CNS/Ocular Diseases. Financially, the company ended 2019 with $1.55 billion in cash, cash equivalents, and marketable securities, positioning it to fund its operations and continued pipeline development. While the company reported a net loss of $886.1 million for the year, reflecting significant investment in R&D, it anticipates future growth driven by its expanding commercial product portfolio and promising late-stage pipeline candidates like lumasiran for primary hyperoxaluria type 1 (PH1). Strategic collaborations with major players like Regeneron and Sanofi Genzyme continue to be a cornerstone of Alnylam's development and commercialization strategy.

Alnylam Pharmaceuticals reported its 2018 fiscal year results, marking a significant transition to a commercial-stage biopharmaceutical company with the launch of its first RNAi therapeutic, ONPATTRO®, in August 2018 for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis. The company generated $12.5 million in net revenue from ONPATTRO sales in 2018, with expansion into Europe occurring in the latter half of the year. Financially, Alnylam ended 2018 with strong liquidity, holding $1.13 billion in cash, cash equivalents, and marketable securities, bolstered by a $382 million public offering in January 2019. The company's pipeline remains robust, with five late-stage investigational programs advancing. These include vutrisiran for ATTR amyloidosis, givosiran for acute hepatic porphyria (AHP) where top-line Phase 3 data was positive, lumasiran for primary hyperoxaluria type 1, fitusiran for hemophilia (partnered with Sanofi Genzyme), and inclisiran for hypercholesterolemia (partnered with The Medicines Company). Alnylam's strategic restructuring of its alliance with Sanofi Genzyme in January 2018 clarified global rights for ONPATTRO and vutrisiran to Alnylam, and for fitusiran to Sanofi Genzyme, aligning with Alnylam's goal of building a multi-product commercial biopharmaceutical company.

Alnylam Pharmaceuticals, Inc.'s 2017 10-K highlights a pivotal year marked by significant progress in its RNA interference (RNAi) therapeutic pipeline, particularly with patisiran. The company reached a major milestone by filing its first New Drug Application (NDA) with the FDA and a Marketing Authorisation Application (MAA) with the EMA for patisiran, targeting hereditary transthyretin-mediated (hATTR) amyloidosis. Regulatory reviews are underway with anticipated action dates in 2018, positioning Alnylam for potential product launch and revenue generation within the year. Financially, Alnylam strengthened its position by completing two public offerings that raised substantial net proceeds, ending the year with a robust cash balance. The company continues to invest heavily in research and development to advance its Alnylam 2020 strategy, aiming to have three marketed products and ten clinical-stage programs by the end of 2020. Key collaborations, notably with Sanofi Genzyme and The Medicines Company, remain central to its development and commercialization efforts, with recent amendments to the Sanofi Genzyme agreement significantly reshaping global rights for key pipeline assets.

Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2016 10-K, highlighting a significant focus on its RNA interference (RNAi) therapeutic platform. The company is advancing its "Alnylam 2020" strategy with the goal of becoming a multi-product commercial-stage biopharmaceutical company by the end of 2020, aiming for three marketed products and ten RNAi therapeutic clinical programs. The company's lead candidate, patisiran, for hereditary TTR-mediated amyloidosis (hATTR), is in Phase 3 development with top-line data expected mid-2017, and potential regulatory submissions planned for late 2017. Significant R&D investments continued in 2016, reflecting the advancement of a broad pipeline across three strategic therapeutic areas: Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases. The company also detailed progress in its manufacturing capabilities and global expansion, including its operational manufacturing facility for patisiran and construction of a new drug substance facility. Despite a substantial net loss of $410.1 million for 2016, driven by significant R&D expenses, Alnylam maintained a strong cash position of $942.6 million in cash, cash equivalents, and marketable securities at year-end, supported by strategic collaborations with companies like Sanofi Genzyme and The Medicines Company.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics based on RNA interference (RNAi). The company's strategy centers on its proprietary GalNAc-conjugate delivery platform for siRNAs, targeting genetically validated, liver-expressed genes. Alnylam has a pipeline across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases. The company has significant ongoing clinical development, with its most advanced program, patisiran for TTR-mediated amyloidosis (ATTR), in Phase 3 trials and expected to report data in 2017. Other key programs include revusiran (also for ATTR), fitusiran for hemophilia, and ALN-PCSsc for hypercholesterolemia. The company's financial performance is characterized by substantial R&D expenses and net losses, with revenues primarily driven by collaboration agreements. A substantial cash position and strategic alliances, particularly with Sanofi Genzyme, provide financial runway for continued development towards achieving its 'Alnylam 2020' goals.

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. As of their February 13, 2015, 10-K filing, the company was in the clinical stage of development, with no products yet approved for commercial sale. Their primary strategy centers on using proprietary RNAi technology, particularly their GalNAc-conjugate delivery system, to create novel treatments for a range of diseases. The company has outlined an "Alnylam 2020" plan, aiming for three marketed products and ten clinical programs by the end of 2020. Key development areas include Genetic Medicines for rare diseases (with their most advanced program, patisiran, targeting transthyretin-mediated amyloidosis), Cardio-Metabolic Diseases (targeting conditions like hypercholesterolemia), and Hepatic Infectious Diseases (such as Hepatitis B). Significant recent events include a substantial public offering in January 2015, raising approximately $496.4 million in net proceeds, and a strategic collaboration with Genzyme announced in January 2014, which includes significant upfront payments and milestone potential. Financially, Alnylam reported substantial operating losses, consistent with its development-stage status, with an accumulated deficit of $956.6 million at the end of 2014. Despite ongoing losses, the company ended 2014 with a strong cash position of $881.9 million in cash, cash equivalents, and marketable securities, bolstered by the January 2015 public offering and the Genzyme collaboration, providing runway for continued investment in their robust pipeline.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its annual results for the fiscal year ending December 31, 2013. The company is a biopharmaceutical firm focused on developing RNA interference (RNAi) therapeutics, a novel class of medicines targeting genetic diseases. Key to Alnylam's strategy is its "Alnylam 5x15" program, aiming to have 6-7 genetic medicine candidates in clinical development, including at least two in Phase 3, by the end of 2015. The company's most advanced program, patisiran (ALN-TTR02), targets transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) and has shown positive results in Phase 2 trials with initiation of a Phase 3 APOLLO trial. Significant recent developments include the planned acquisition of Sirna Therapeutics' RNAi assets from Merck and a major global strategic collaboration with Genzyme, a Sanofi company, for the development and commercialization of its genetic medicine pipeline outside of North America and Western Europe. This collaboration, including a $700 million equity investment from Genzyme, significantly strengthens Alnylam's financial position and provides substantial resources for advancing its pipeline. Financially, Alnylam reported net revenues from collaborators of $47.2 million, a decrease from $66.7 million in 2012, primarily due to the completion of certain collaboration obligations. Operating expenses were $140.1 million, a decrease from $196.2 million in 2012, mainly due to the absence of a significant restructuring charge incurred in the prior year, although R&D expenses increased to support pipeline advancement. The company reported a net loss of $89.2 million for 2013, compared to a net loss of $106.0 million in 2012. Alnylam ended the year with a strong cash position of $350.5 million, bolstered by its January 2013 public offering and the anticipated Genzyme investment, providing ample runway to fund its ongoing research and development activities.

Alnylam Pharmaceuticals, Inc.'s 2012 10-K filing highlights a company in the early stages of developing novel RNA interference (RNAi) therapeutics. The company's core strategy, "Alnylam 5x15," aims to have five RNAi therapeutic programs in clinical development by the end of 2015. Financially, Alnylam reported a net loss of $106 million for 2012, continuing its trend of losses as it invests heavily in research and development. The company secured significant funding through a public offering in early 2013, raising approximately $173.6 million, which will be used to advance its clinical pipeline. Key partnerships with companies like The Medicines Company (MedCo) and Genzyme are crucial for developing and commercializing its product candidates in specific territories. The company emphasizes its strong intellectual property portfolio and its leading position in RNAi technology. Despite the significant risks associated with early-stage drug development and the competitive landscape, Alnylam appears to be strategically positioning itself for future growth by focusing on high unmet medical needs and leveraging its platform technology.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics based on RNA interference (RNAi). In 2011, the company continued to advance its pipeline, with key programs like ALN-TTR for transthyretin-mediated amyloidosis (ATTR) and ALN-APC for hemophilia showing progress. The company reported preliminary Phase I data for ALN-TTR01 demonstrating dose-dependent reduction in serum TTR levels and for ALN-PCS showing significant silencing of PCSK9 protein levels and reductions in LDL-c. Financially, Alnylam continued to operate at a net loss, with significant investments in research and development. The company ended 2011 with a solid cash position of $260.8 million, supported by collaboration revenues primarily from Roche/Arrowhead and Takeda. However, total revenues decreased compared to the prior year, and the company implemented a strategic restructuring in early 2012, reducing its workforce by approximately 33% to focus resources on its highest-value opportunities. Significant legal proceedings related to intellectual property with Tekmira and other parties were ongoing, posing a potential risk to the company's operations and financial performance.

Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2010 annual report, highlighting its strategic focus on RNA interference (RNAi) therapeutics. The company is advancing its 'Alnylam 5x15' strategy, aiming to bring five RNAi therapeutic programs into advanced clinical development by the end of 2015. Alnylam is currently developing three core programs: ALN-TTR for transthyretin-mediated amyloidosis (ATTR), ALN-PCS for severe hypercholesterolemia, and ALN-HPN for refractory anemia. Financially, Alnylam reported net revenues from research collaborators of $100.0 million for 2010, with total operating expenses of $144.1 million, resulting in a net loss of $43.5 million. The company ended 2010 with $349.9 million in cash, cash equivalents, and marketable securities, indicating a strong cash position to fund ongoing research and development activities. Alnylam also emphasized its robust intellectual property portfolio and a strong base of strategic alliances with major pharmaceutical companies, which provide significant financial support and operational capabilities.

This 10-K filing for Alnylam Pharmaceuticals, Inc. as of December 31, 2009, highlights a company in the developmental stages of its business, heavily focused on the research and development of RNA interference (RNAi) therapeutics. While the company has no products on the market, it has established a robust pipeline of investigational drugs targeting various genetic diseases. The filing emphasizes significant investments in R&D, a key indicator for biotechnology firms, and outlines potential risks associated with drug development, regulatory approvals, and market adoption. Financially, Alnylam's operations are characterized by substantial research and development expenses, leading to net losses, which is typical for companies in this sector. The company relies on collaborations and strategic partnerships to advance its pipeline and fund its operations. Investors should pay close attention to the company's cash runway, its progress in clinical trials, and its ability to secure future funding and commercialize its innovative therapies. The lack of current revenue streams means that future growth is entirely contingent on the successful development and launch of its drug candidates.

This 10-K filing for Alnylam Pharmaceuticals, Inc. (ALNY) as of March 2, 2009, provides a snapshot of the company during a critical development phase. The company is focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. While the filing details significant research and development activities, investors should note that Alnylam is an early-stage biopharmaceutical company with no approved products and is heavily reliant on its pipeline and collaborations for future revenue. The financial statements indicate substantial operating losses, as is typical for companies at this stage of development, underscoring the inherent risks associated with investing in biotechnology. Key to Alnylam's strategy is its robust intellectual property portfolio and its partnerships with major pharmaceutical companies, which provide crucial funding and expertise. The risk factors section highlights the significant challenges ahead, including the inherent uncertainties of drug development, regulatory approvals, intellectual property protection, and market competition. Investors should carefully assess these risks in conjunction with the company's long-term growth potential derived from its innovative RNAi platform.

This 10-K filing for Alnylam Pharmaceuticals, Inc. (ALNY) as of March 10, 2008, details the company's progress and risks in the emerging field of RNA interference (RNAi) therapeutics. Alnylam is focused on developing a pipeline of novel RNAi therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system/ocular diseases. The company's strategy involves building a broad portfolio through internal development and strategic collaborations, with key partnerships mentioned being with Merck and sanofi-aventis. Significant investment is being made in research and development, which is reflected in the company's financial performance, with an emphasis on future growth potential rather than current profitability.

This 2006 10-K filing for Alnylam Pharmaceuticals, Inc. (ALNY) details a company in the early stages of drug development, with a significant focus on RNA interference (RNAi) therapeutics. Alnylam had no products approved for sale and generated no product revenue during the period. Its primary activities revolved around research and development, with substantial investments in its scientific platform and pipeline. The company's financial strategy was heavily reliant on equity financing and strategic partnerships to fund its extensive R&D efforts. Investors should note that Alnylam was operating at a loss, a typical characteristic of pre-revenue biotechnology firms. The company's valuation and future prospects were therefore tied to the successful advancement of its drug candidates through clinical trials and regulatory approval. The risk factors section is crucial for understanding the inherent uncertainties and challenges associated with developing novel therapeutics in this nascent field, including the long timelines, high costs, and significant regulatory hurdles involved. The company's ability to secure future funding and maintain its intellectual property were critical for its long-term survival and growth.

Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2005 annual report, highlighting its pioneering work in RNA interference (RNAi) therapeutics. The company is focused on developing novel drugs that leverage the natural RNAi mechanism to selectively silence gene activity, addressing a broad range of diseases. ALNY's most advanced candidate, ALN-RSV01 for RSV infection, has entered Phase I clinical trials, with a pandemic flu therapeutic candidate expected to reach the IND stage by the end of 2006. The company's strategy centers on building a robust pipeline of proprietary RNAi therapeutics and forming strategic alliances with major pharmaceutical companies like Novartis and Merck. These collaborations are crucial for Alnylam's financial and operational growth, providing significant funding and development expertise. Alnylam has also secured a strong intellectual property portfolio, which it considers vital for its competitive advantage. Despite early-stage development and significant investment in research and development, Alnylam remains focused on its long-term vision of establishing RNAi therapeutics as a major drug class.

This 2004 10-K filing from Alnylam Pharmaceuticals, Inc. (ALNY) provides a foundational look at the company as it was in early 2005. As a relatively early-stage biotechnology firm at the time, Alnylam's focus was on its core business: the research and development of novel therapeutics based on RNA interference (RNAi). The company was actively building its intellectual property portfolio and seeking strategic partnerships to advance its pipeline. Investors would have been looking at the company's progress in early-stage drug discovery and development, its financial resources, and its management team's ability to execute on its ambitious scientific and commercial goals. Key areas of interest for investors at this stage include the company's scientific platform, its pipeline candidates and their potential therapeutic areas, the competitive landscape within RNAi technology, and the financial burn rate as the company invested heavily in R&D. The filing indicates a strong emphasis on building a defensible intellectual property position and a commitment to exploring the vast potential of RNAi for various human diseases. The financial health, while likely characterized by net losses typical of R&D-intensive biotech, would be scrutinized for cash runway and funding strategies.